Article

IC pain perception unaltered by pH neutralization

San Francisco--Results from a study evaluating the effect of urinary pH alteration in patients with interstitial cystitis suggest little benefit is likely gained from alkalinizing the urine to a neutral pH. Nevertheless, the question of how urine pH affects IC symptoms remains unanswered and requires further study, concluded the authors, from the University of British Columbia, Vancouver.

Related Videos
Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
Special Report: Tips for PCPs on evaluating prostate cancer risk
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
Special Report: Tailoring prostate cancer care for older adults
Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
Special Report: New strategies emerge for metastatic prostate cancer
Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
4 experts in this video
Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
1 expert is featured in this series.
Case 2: A 63-Year-Old Man With Recurrent HSPC
Related Content
Expert discusses the promise of emerging MISTs for BPH
May 23rd 2025

Expert discusses the promise of emerging MISTs for BPH

James C. Ulchaker, MD Hannah Clarke
James C. Ulchaker, MD, shares his insights on the current range of BPH therapies.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
May 21st 2025

FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

Hannah Clarke
The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
May 20th 2025

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer

Hannah Clarke
Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
May 20th 2025

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

Hannah Clarke
The phase 3 study design will now be submitted for final review by the agency.
© 2025 MJH Life Sciences

All rights reserved.